NADH-cytochrome b5 reductase 3 (CYB5R3) is a pivotal flavoprotein enzyme that transfers electrons from NADH to cytochrome b5, playing a critical role in methemoglobin reduction, lipid elongation, cholesterol biosynthesis, and systemic nitric oxide (NO) / soluble guanylyl cyclase (sGC) signaling. As a key node in cellular redox homeostasis and mitochondrial physiology, CYB5R3 has emerged as a high-value therapeutic target in cardiovascular diseases (such as pulmonary hypertension), metabolic syndromes, and oncology (particularly in modulating ferroptosis and cancer cell metabolism).
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CYB5R3 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CYB5R3 Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. Soluble catalytic domain available for enzymatic screening. |
View CYB5R3 Products |
| Gene Delivery | CYB5R3 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and target engagement validation. |
View CYB5R3 Products |
| Benchmark Ab | Anti-CYB5R3 Recombinant Antibody Sequence-verified positive control for Western Blot, ELISA, and intracellular localization assays. |
View CYB5R3 Products |
| Validator | CYB5R3 siRNA Set Validated sequence pool for target knockdown and specificity verification in phenotypic assays. |
View CYB5R3 Products |
| Related Target A | CYB5A (Cytochrome b5 Type A) The physiological electron acceptor of CYB5R3; essential for reconstructing cell-free electron transfer assays. |
View CYB5A Products |
| Related Target B | NQO1 (NAD(P)H Quinone Dehydrogenase 1) Parallel cytosolic redox enzyme; critical for counter-screening and metabolic synergy studies in oncology. |
View NQO1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Enzymatic activity preservation in vitro | Recombinant CYB5R3 soluble domain expressed with native folding and verified cofactor (FAD) binding. |
| Subfamily selectivity screening | Homolog panel proteins (CYB5R1, CYB5R2, CYB5R4) strictly verified by mass spectrometry to avoid off-target profiling errors. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live CYB5R3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of CYB5R3 is undergoing a significant transition. Historically studied for its role in congenital methemoglobinemia, modern drug discovery is actively positioning CYB5R3 as a master regulator of redox-driven pathophysiology. Major pharmaceutical players and academic consortia are shifting focus from simple enzyme replacement concepts to the development of highly selective small molecule inhibitors and allosteric activators.
In cardiovascular medicine, modulating the CYB5R3-Cytochrome b5-sGC pathway represents a novel approach to treat resistant hypertension and systemic sclerosis. Concurrently, in oncology, the inhibition of CYB5R3 is being investigated to disrupt cancer cell redox buffering, thereby sensitizing therapy-resistant solid tumors to ferroptosis-inducing agents and radiation therapy.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Consortia, Biotech Startups | Solid Tumors, Ferroptosis Induction | High-throughput cell-free enzymatic assay (Requires high-purity recombinant CYB5R3 and CYB5A) |
| Small Molecule Activators | Pharma / Cardiovascular Specialists | Pulmonary Hypertension, sGC Dysfunction | Target engagement and conformational stability assays (Requires sequence-verified WT protein) |
| Gene & RNA Therapies | Rare Disease Innovators | Methemoglobinemia Type I & II | Cellular rescue and overexpression validation (Requires high-titer Lentivirus and validated siRNA) |